Jon Congleton
Chief Executive Officer chez MINERALYS THERAPEUTICS, INC.
Fortune : 19 M $ au 31/03/2024
Profil
Jon Congleton is currently the Chief Executive Officer & Director at Mineralys Therapeutics, Inc. and an Operating Partner at Catalys Pacific LLC.
Previously, he served as the President & Chief Executive Officer at Alpine Immune Sciences, Inc. and the President, Chief Executive Officer & Director at Ipi Legacy Liquidation Co. He also held the position of President, Chief Executive Officer & Director at Nivalis Therapeutics, Inc. from 2014 to 2017.
Prior to that, he worked as the Senior VP-Global Brand Strategic Marketing at Teva Pharmaceutical Industries Ltd.
and as the Vice President & General Manager at Teva Neuroscience, Inc. Mr. Congleton completed his undergraduate degree at Kansas State University.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
15/03/2024 | 1 454 235 ( 2,93% ) | 19 M $ | 31/03/2024 |
Postes actifs de Jon Congleton
Sociétés | Poste | Début |
---|---|---|
MINERALYS THERAPEUTICS, INC. | Chief Executive Officer | 01/11/2020 |
Catalys Pacific LLC
Catalys Pacific LLC Investment ManagersFinance Catalys Pacific LLC (Catalys Pacific) is a venture capital firm founded in 2018 by BT Slingsby. The firm is headquartered in Cayman Islands. | Private Equity Investor | - |
Anciens postes connus de Jon Congleton
Sociétés | Poste | Fin |
---|---|---|
IPI LEGACY LIQUIDATION CO | Chief Executive Officer | 05/05/2020 |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Chief Executive Officer | 15/01/2017 |
ALPINE IMMUNE SCIENCES, INC. | Chief Executive Officer | 01/01/2017 |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Sales & Marketing | - |
Teva Neuroscience, Inc.
Teva Neuroscience, Inc. Pharmaceuticals: MajorHealth Technology Teva Neuroscience, Inc. developed and marketed drugs for neurological disorders. The company's product COPAXONE was used to reduce relapses caused by relapsing-remitting multiple sclerosis. It also offered treatment for Parkinson's disease. Teva Neuroscience was founded in 1997 and was located in Kansas City, MO | Corporate Officer/Principal | - |
Formation de Jon Congleton
Kansas State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 4 |
---|---|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
IPI LEGACY LIQUIDATION CO | Health Technology |
ALPINE IMMUNE SCIENCES, INC. | Health Technology |
MINERALYS THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Teva Neuroscience, Inc.
Teva Neuroscience, Inc. Pharmaceuticals: MajorHealth Technology Teva Neuroscience, Inc. developed and marketed drugs for neurological disorders. The company's product COPAXONE was used to reduce relapses caused by relapsing-remitting multiple sclerosis. It also offered treatment for Parkinson's disease. Teva Neuroscience was founded in 1997 and was located in Kansas City, MO | Health Technology |
Catalys Pacific LLC
Catalys Pacific LLC Investment ManagersFinance Catalys Pacific LLC (Catalys Pacific) is a venture capital firm founded in 2018 by BT Slingsby. The firm is headquartered in Cayman Islands. | Finance |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Health Technology |